Search results for #Amyloidosis
We’re grateful that we had the opportunity to attend @EMN_EuMMnet’s #EMN2024 & @BritSocHaem's #BSH2024. It was an honor to connect with the #hematology community and to present pooled safety data on our investigational new #amyloidosis treatment.
Stay current on important advances in ATTR-CM management with our Virtual Q&A CME featuring @abouezzeddine of @MayoClinic and @omarsiddiqi of @The_BMC Learn more here 👉tinyurl.com/ATTRCMHS #HFpEF #amyloidosis #nuclearimaging
$pfe #vyndamax sales for ATTR #amyloidosis were very impressive . $1.14B for Q1, up from $686M in Q1 of last year. thats amazing growth for a 6 yr old drug. Well on its way to being a $5B+ drug. with 5 more drugs expected in ATTR in the next 5 years, this is going to be a big…
Check out my latest article on the role of serum biomarkers in Cardiac amyloidosis! 📚🤔 @CardioFJD @alvaroacena @ResiSec @JovenesSec @Borjaibanez1 @CNIC_CARDIO #Amyloidosis #CardioEd mdpi.com/2308-3425/11/5…
Don’t forget on the interesting topics on #satellitesymposium, for the #amyloidosis enthusiast, on all #ATTR #cardiacamyloidosis @ThibaudDamy
Excited to share this manuscript on #atrialfibrillation in #ATTR #amyloidosis.🫀AF is common, is associated with a worse prognosis, but not independently of other risk factors. No impact on #tafamidis effectiveness. @JACCJournals @dr_pavia @MargotDavisMD sciencedirect.com/science/articl…
So clinical trials for partner are (fingers crossed) starting in June with screening end of May. I can only hope he won’t be the 1 to receive the placebo. It’s a long trial, the first few months will be lots of visits/follow ups but if successful, groundbreaking #amyloidosis
Encouraging anyone in Coffs Harbour interested in learning more about #amyloidosis to attend this education session @cassia_kessler @DrElleRye @gjmccaughan @DrNatashaGorrie @ISA_Amyloidosis @OzAmyloidosis
Encouraging anyone in Coffs Harbour interested in learning more about #amyloidosis to attend this education session @cassia_kessler @DrElleRye @gjmccaughan @DrNatashaGorrie @ISA_Amyloidosis @OzAmyloidosis
A case of PiB and NaF PET/CT imaging in a patient with ATTR-CA before and after Rx with Tafamidis. #amyloidosis #ThinkAmyloid Read here👉bit.ly/3xVm34x #CVNuc @MyASNC
Thanks for outlining our paper @Transplant_Doc . Great work from @LopedotePaolo , @MMoscvin @nickbolli and all the other trainees @TheBianchiLab ! #amyloidosis
Thanks for outlining our paper @Transplant_Doc . Great work from @LopedotePaolo , @MMoscvin @nickbolli and all the other trainees @TheBianchiLab ! #amyloidosis
AL amyloidosis response: a move in the “light” direction @ADispenzieri #mmsm #amyloidosis @BloodJournal ashpublications.org/blood/article/…
Patients with no detectable FLC by mass spectrometry have significantly better OS and organ response irrespective of conventional hematologic response #mmsm #amyloidosis @JBomsztyk @awechalekar @BloodJournal ashpublications.org/blood/article-…
CHIP is more prevalent in AL Amyloidosis patients than the general population, but not associated with worse survival outcomes #mmsm #amyloidosis @TheBianchiLab @nickbolli @BloodAdvances ashpublications.org/bloodadvances/…
#Myeloma Paper of the Day: Study of real-world outcomes in modified Mayo Stage IIIa/b cardiac AL #amyloidosis finds ECOG PS ≤1, NYHA FC ≤2, achieving heme response ≥VGPR & cardiac response ≥PR after 1st-line treatment portended a good prognosis: pubmed.ncbi.nlm.nih.gov/38672674/.
Great overview of current and future therapies for #amyloidosis by @akates1 ! With stabilizers and silencers on the market plus 🤞depleters in trials, it's an exciting time in the field. @wuSTLAmyloid @wuSTLmed @wu
Great day today at the 3rd #midwestcellular conference! I got to talk about high risk #myeloma. I’d say HRMM was my arch-nemesis if it weren’t for Stage IV AL #amyloidosis. That’s why @karmanoscancer has the AFFIRM-AL trial open. clinicaltrials.gov/study/NCT04973…
Tour de force on light chain #amyloidosis by @CyclingDoctor @WashUOnc! Highlights⚡️ case on Facotr X deficiency in AL, upcoming anti-fibril "depleter" therapies, trials of Immunotherapy @WUSTLmed
Dr. Stephanie Geisler, expert #amyloidosis neurologist, discusses neurologic involvement- fantastic talk! Expand your neuro sx review beyond - "any numbness in your feet?" to capture patients at risk of #amyloidosis.